While metastatic tumor samples and cell line models have been critical to understanding how AR reactivation occurs, they often lack the ability to fully replicate the complexity and heterogeneity of the clinical TME, which includes immune and stromal factors [36]. The gene discussed is AR; the disease is neoplasm.